BYL719 treatment abolished PIK3CAH1047R‐mediated anti‐HER2 resistance, indicating that the combination of lapatinib and BYL719 provides a promising strategy to overcome the dual genomic carcinogen of mutated‐PI3Kα and enriched‐HER2 in breast cancer. Here, ERBB2 is linked to breast cancer.